Catch It Early: The Science and Limits of Cancer Screening

An estimated 2.1 million Americans will receive a cancer diagnosis in 2026, while more than 626,000 will die from the disease. That is roughly 5,800 new cases and 1,700 deaths every day. Since 1991, declines in smoking and advances in early detection have helped avert 4.8 million cancer deaths, pushing the overall five-year survival rate to a record 70 percent [1]. Yet the screening tools driving those gains carry an underappreciated downside: some detect cancers that never needed finding.

Where Screening Saves the Most Lives

The evidence for early detection is strongest where cancers progress through identifiable precancerous stages or are highly curable when caught localised. Cervical cancer screening via Pap smears and HPV testing has reduced mortality by up to 80 percent in countries with high participation [2]. In December 2025, the American Cancer Society updated its cervical screening guidelines to include self-collected HPV testing, a move expected to expand access significantly [3].

Colorectal cancer screening tells a similar success story. Colonoscopy and the faecal immunochemical test (FIT) detect and remove precancerous polyps before malignant transformation. Recent data show FIT lowers colorectal cancer death risk by roughly 33 percent, while colonoscopy reduces mortality by as much as 73 percent [4]. For high-risk smokers, annual low-dose CT scans cut lung cancer deaths by 20 to 24 per cent, according to the U.S. National Lung Screening Trial and the European NELSON trial, with women in the latter seeing reductions of up to 33 per cent [5].

The biology is straightforward: earlier-stage tumours carry lower metastatic burden, respond better to surgery and radiation, and demand less toxic systemic therapy. Stage at diagnosis remains one of the strongest predictors of survival across virtually all cancer types [1].

When Screening Finds Too Much

Detection, however, is not always rescue. Overdiagnosis, the identification of cancers that would never have caused symptoms or death during a patient’s lifetime, is one of oncology’s most important yet least discussed risks.

Prostate cancer is the best-studied case. PSA-based screening detects a substantial share of low-grade, indolent tumours (Gleason score 6) that carry minimal mortality risk, yet many patients undergo radical prostatectomy or radiation, procedures with meaningful risks of incontinence and sexual dysfunction [6]. Active surveillance is increasingly recommended as the safer alternative for slow-growing disease.

Thyroid cancer illustrates the pattern on a larger scale. Incidence has surged roughly 250 per cent since 1990, driven almost entirely by ultrasound detection of small papillary microcarcinomas that would never have been clinically diagnosed. Modelling data published in 2026 estimate that 72 to 94 percent of papillary thyroid cancers diagnosed between 1991 and 2019 were overdiagnosed [7]. In mammography programmes, breast cancer overdiagnosis is estimated at 11 to 16 per cent of screen-detected cases, rising with age, from about 11.5 per cent at age 50 to nearly 24 per cent at age 74 [8].

Not Everyone Benefits Equally

Even where screening works, its benefits are unevenly distributed. The American Association for Cancer Research’s 2024 Cancer Disparities Progress Report found that racial and ethnic minorities, lower-income populations, and rural communities remain significantly less likely to complete recommended screenings, yet bear disproportionately higher rates of late-stage diagnosis and cancer death [9]. A 2021 study in JAMA Network Open confirmed that women in rural U.S. communities were less likely to adhere to colorectal cancer screening guidelines than their urban counterparts [10]. Structural barriers, including gaps in insurance coverage, distance from screening facilities, language access, and historical medical mistrust, drive these disparities far more than individual knowledge or motivation.

The Next Frontier: Blood-Based Detection

On the horizon, multi-cancer early detection (MCED) tests, liquid biopsies that screen for dozens of cancer types from a single blood draw, are advancing through large-scale clinical trials. These tests analyse cell-free DNA and other biomarkers to flag cancer signals before symptoms appear. However, no MCED test has yet received regulatory approval, and experts caution that whether this first generation of tests translates into survival benefits remains unproven [11].

Current Evidence-Based Screening Recommendations

For now, the evidence supports targeted screening matched to individual risk:

• Colorectal cancer: FIT annually or colonoscopy every 10 years, starting at age 45
• Breast cancer: Mammography every two years, ages 40 to 74
• Cervical cancer: HPV testing every five years from age 25 (per ACS 2025 guideline), or Pap smear every three years from age 21
• Lung cancer: Annual low-dose CT for current or former heavy smokers, ages 50 to 80
• Prostate cancer: Shared decision-making about PSA testing, ages 55 to 69 (earlier for high-risk groups)

What to Take Away

Cancer screening saves lives, but it is a medical intervention, not a reflex. The greatest benefit comes not from seeking every available test but from following evidence-based guidelines matched to your age and risk profile. The most important step you can take is to have an honest conversation with your doctor about which screenings are right for you, and what a positive result would actually mean.

References

1. Siegel RL, Kratzer TB, Wagle NS, Jemal A (2026) Cancer statistics, 2026. CA Cancer J Clin. doi:10.3322/caac.70043.
2. National Cancer Institute. Cervical Cancer Screening (PDQ), Health Professional Version. cancer.gov.
3. American Cancer Society (2025) Updated Cervical Cancer Screening Guidelines Include Self-Collection for HPV Testing. pressroom.cancer.org.
4. PMC (2024) Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death. JAMA. See also: Systematic Review and Meta-Analysis of CRC Screening Effectiveness, Cancers 15(4):1172 (2023). PubMed Central.
5. de Koning HJ et al. (2020) Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 382:503-513. doi:10.1056/NEJMoa1911793.
6. Klotz L (2022) Overdiagnosis in urologic cancer. World J Urol 40:1-8. doi:10.1007/s00345-020-03523-2.
7. Medscape (2026) Majority of Papillary Thyroid Cancer Cases Are Overdiagnosis. See also: Nature Reviews Endocrinology (2025) Unravelling the rise in thyroid cancer incidence. doi:10.1038/s41574-025-01168-y.
8. Kim YJ et al. (2023) Overdiagnosis Due to Screening Mammography for Breast Cancer among Women Aged 40 Years and Over: A Systematic Review and Meta-Analysis. Diagnostics 13:1034. PubMed Central.
9. American Association for Cancer Research (2024) AACR Cancer Disparities Progress Report 2024. Cancer Epidemiol Biomarkers Prev 33(7):870. doi:10.1158/1055-9965.EPI-24-0658.
10. Shete S et al. (2021) Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA Netw Open 4:e2128000. doi:10.1001/jamanetworkopen.2021.28000.
11. Multi-cancer early detection: from promise to practice and the next frontier. Cancer Biol Med (2025). doi:10.20892/j.issn.2095-3941.2025.0664.